Fionn, an integral member of the Cardiothoracics Team while in BioInnovate, is now CEO of OneProjects, an innovative medical device start-up he co-founded with teammate, Christoph Hennersperger. The company has headquarters in both Dublin and Munich, with its ambition to revolutionise the treatment for paroxysmal and persistent Atrial Fibrillation (AFib), which affects millions of people worldwide.
OneProjects is continuing to develop its cornerstone technology, VERAFEYE, a digitally connected medical device that will enable clinicians to precisely monitor, verify and improve in-procedural efficiency and efficacy, reduce re-intervention rates and produce significant patient and economic benefits within the AFib space. The founders were successful in receiving seed funding from Enterprise Ireland to accelerate commercialisation of the VERAFEYE technology. The team are currently seeking Series A funding to bring the project to First in Man clinical trials. It is envisaged that OneProjects will spin-out in Q1 2019 and progress on a commercial pathway leading to market access in 2021.
The founding team met on the Bioinnovate program in 2015. The fellowship program facilitated vast clinical access and opened the doors to a willing and engaged commercial network. The Bioinnovate program gave us the platform to approach the commercial development of VERAFEYE in a comprehensive 360 degree fashion and enhanced the skills needed to solve such a large and significant unmet need